Skip to content
Clinical Trials – home
LatviaBack to Latvia

Clinical trials in Sigulda – page 6

116 clinical trials in Sigulda, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Sigulda at a glance
116
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

116 trials in Sigulda

Open in trial search

Atrial fibrillation

Not recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:LatviaLatvia
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Hypertriglyceridaemia

Not recruiting

Study on the Effects of Pegozafermin and Simvastatin for Patients with Severe High Triglycerides

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:89bio Inc.

Neurodermatitis

Not recruiting

Study of Rocatinlimab in Adults with Prurigo Nodularis Not Adequately Controlled by Topical Treatments

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Crohn's disease

Not recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Asthma

Not recruiting

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Chiesi Farmaceutici S.p.A.

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Serplulimab
  • Sponsor:Shanghai Henlius Biotech Inc.

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:4d Molecular Therapeutics Inc.

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Other cities in Latvia

The busiest research cities in the country

All 18 cities in Latvia

Clinical research in Sigulda

What the registry says about research in the country

01 Diabetes Research

Clinical investigations focusing on advancing treatment options for patients with Type 2 Diabetes who aren't achieving optimal control with current medications.

  • Therapeutic Focus: Blood glucose management
  • Treatment Combination Studies
  • Metabolic Disease Research

The research evaluates the effectiveness of combining gliclazide MR with existing diabetes medications to improve glycemic control, particularly focusing on HbA1c reduction in patients with inadequate response to current treatments.

02 Metabolic Disorders

Innovative research exploring combination therapy approaches in metabolic disease management, specifically targeting patients with suboptimal response to standard treatments.

  • Medication Optimization
  • Glycemic Control Studies
  • Treatment Enhancement Research

This clinical investigation aims to advance our understanding of treatment optimization for patients requiring additional therapeutic support beyond initial medication regimens.

03 Treatment Efficacy

Comprehensive evaluation of treatment effectiveness in diabetes management, focusing on medication combinations to achieve better patient outcomes.

  • Safety Assessment
  • Clinical Response Monitoring
  • Long-term Effectiveness

The research examines both the efficacy and safety profiles of combined therapeutic approaches over a 24-week period, providing valuable insights into treatment optimization strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.